


Antibacterial chemotherapeutics 2

1. β -lactame antibiotics
 - 1.1 Penicillins
 - 1.2 Cephalosporins
2. Macrolide antibiotics
3. (Poly)peptide antibiotics
4. Aminoglycoside antibiotics


β -lactame antibiotics

Lactams = internal amides of amino acids




6-aminohexanoic acid
 ϵ -aminocaproic acid


azepan-2-on
 ϵ -caprolactam
6-hexanlactam




piperidin-2-on
 δ -valerolactam
5-pentanlactam



pyrrolidin-2-on
 γ -butyrolactam
4-butanlactam




β -lactame antibiotics



Penicillins

N-acyl-6-aminopenicillanic acids



Cephalosporins

N-acyl-7-aminocephalosporanic acids

Mechanism of action

- inhibition of cell wall synthesis by binding to specific proteins

Penicilins History

World

1928(9) – **Alexander Fleming** – isolated a liquid concentrate inhibiting growth of bacteria from a mould of *Penicillium* species

1939 - 1943 Fleming, Florey, Chain & Johnson – isolation and constitution of penicillins


1945-Nobel prize for Fleming, Florey and Chain

Czech territory

1943 – Málek, Fragner, Herold, Hais etc. – Mykoin BF 510


Penicillins

The initial „amorphous penicillin“ was a mixture of several compounds:



Penicillins


Benzylpenicillin and its problems



• production of benzylpenicillin by the mould by addition of phenylacetic acid into its broth

Problems:


- weak binding to plasmatic proteins \Rightarrow fast excretion \Rightarrow frequent administration is necessary
- instability in acid media of stomach (see reaction scheme) \Rightarrow impossibility of p.o. application



Penicillins

Benzylpenicillin and its problems

3. Sensitivity to penicillinases (β -lactamases – enzymes catalysing hydrolytic cleavage of the β -lactame ring) – see the scheme




4. Rel. narrow spectrum – only G^+ strains (*Streptococcus*, *Staphylococcus*, *Clostridium*, *Neisseria*, *Corynebacterium*, *Bacillus anthracis* ...)

5. Inducing allergies – anaphylactic shock – caused by 6-aminopenicillanic acid as the impurity – resolved by better purification (chromatography)


Penicillins

Resolving of benzylpenicillin problems

Ad 1. (necessity of frequent application) – poorly soluble salts with organic bases



benzathine benzylpenicillin
Pendepon[®] inj. sic.




procaine benzylpenicillin
Prokain Penicilin G[®] Biotika inj. sic.

•depot (= long acting) forms for i.m. injections

Penicillins

Resolving of benzylpenicillin problems

Ad 2. – ↑ of stability in acid media



phenoxymethylpenicillin
syn. **penicillin V**



- acquired by addition of phenoxyacetic acid into the broth of the production strain
 - suitable for p.o. administration
- V-Penicilin[®], Ospen[®]

Penicillins

Overall resolving of benzylpenicillin problems – **semi-synthetic penicillins**

• **penicillinamidase (penicillinacylase)** – hydrolyzes acyclic amide bond, not β -lactame ring


• used a microbe which produces it (e.g. *E. coli*)



Penicillins


Mostly semi-synthetic penicillins stable in acid media

- stability against acids is increased by electron-donor substituents in N-acyl side chain (I+ or M+ effect)



ampicillin

Ampicilin[®] cps., inj sic.



R = -H

V-Penicilin[®] tbl., Oспен tbl. obd.

R = -CH₃

R = -CH₂CH₃

phenoxymethylpenicillin


phenethicillin

propicillin


Penicillins

Semi-synthetic penicillins resistant to β -lactamases

- formed by acylation of amino group of 6-aminopenicillanic acid with bulky acyl rest; the lactame ring is then sterically hindered (\Rightarrow protected)



meticillin



R¹ = R² = -H

oxacillin

Prostaphlin[®] eps., inj. sic.

R¹ = -Cl, R² = -H

cloxacillin

R¹ = R² = -Cl

dicloxacillin

R¹ = -Cl, R² = -F

flucloxacillin

syn. floxacillin [USAN]


- resistant also to acid media; the resistance increases
oxacillin < cloxacillin < dicloxacillin = flucloxacillin

Penicillins

An alternative approach to ↑ of resistance to β -lactamases:


β -lactamases inhibitors

- compounds with β -lactam ring which binds to the enzyme active site with greater affinity and block this site
- used in combination with penicillins



clavulanic acid


- isolated from *Streptomyces clavuligerus*
- + amoxicillin (= Amoxiklav[®], Augmentin[®])
- + ticarcillin (= Timentin[®] inj. sic.)



4,4-dioxopenicillanic acid

sulbactam

- Betrimon[®]
- + ampicillin (= Ampisucillin[®] inj. plv. sol.)




tazobactam

- + piperacillin (= Tazocin[®] inj. sic.)

Penicillins

A combination of a penicilline with a β -lactamase inhibitor in one molecule



- a mixed ester of ampicillin and sulbactam with methanediol
- a prodrug of both components

sultamicillin


Bitamon[®] inj. sic., Unasyn[®] tbl. obd.

Penicillins

Penicillins with broadened spectrum

Ad 4. – introduction of a hydrophilic substituent to β -position of the acyl attached to amino group of 6-aminopenicillanic acid \Rightarrow **broadening of the antibacterial spectrum of penicillins also to G⁻ strains**


Compounds with free primary amino group



R = -H **ampicillin**



R = -OH **amoxycillin**

Amoclen[®], Amopen[®]



epicillin

Penicillins with broadened spectrum Ampicillin prodrugs



- hydrolyzed *in vivo* to ampicillin
- achieve significantly higher blood and tissue levels and attains peak blood levels more rapidly than equimolar doses of oral ampicillin
- more frequently used in veterinary (horses) than in human medicine
- models for design of prodrugs of cephalosporins

bacampicillin

ampicillin 1-(ethoxycarbonyloxy)ethylester

pivampicillin

ampicillin


pivaloyloxymethylester

- successful in acute exacerbations of chronic bronchitis

Penicillins with broadened spectrum: ureidopenicillins


Compounds in which the amino group in β -position of the acyl is a part of urea moiety = **ureidopenicillins** = „anti-pseudomonas“ penicillins

•their spectrum includes *Pseudomonas aeruginosa*



piperacillin

Tazocin[®] inj. plv. sol.(+ tazobactam)



R = H-

azlocillin


R= CH₃SO₂-

mezlocillin


•serious infections including *otitis media*, CNS infections ...

Penicillins with broadened spectrum:

- compounds with the additional carboxyl in β -position of the acyl attached to amino group in position 6
- in fact substituted malonic acids monoamides



carbenicillin






ticarcillin

Timentin[®] inj. sic. (+ clavulanic acid)
• infections of bones and junctures
(*Staphylococcus aureus*),
gynecological & abdominal infections ...

- ring analogy (benzene – thiophene)

Cephalosporins


- fungi *Cephalosporium spp.* (1948)




... and other various structures

Cephalosporins


General structure



cephalosporin C
•isolated from *Cephalosporium spp.*




cephamycin C
•isolated from *Streptomyces lactadurans*



Cephalosporins



Properties



- electron pair on N5 is linked to conjugation with double bond \Rightarrow \downarrow of electron density on N5 \Rightarrow \downarrow of nucleophilicity of N5 \uparrow stability in acid media
- also \uparrow resistance to β -lactamases (cephalosporinases)

Cephalosporins

Compounds related to cephalosporin C, i.e. N-acyl derivatives of 7-aminocephalosporanic acid.




* glutarylacylase + D-amino acid oxidase

Cephalosporins


Compounds related to cephalosporin C, i.e. N-acylderivatives of 7-aminocephalosporanic acid

1st generation: for parenteral administration only (not absorbed from GIT)



cephalotin

Cefalotin[®] Biotika inj. sic.




cefaloridin

Cephalosporins

Compounds related to cephalosporin C, i.e. N-acylderivatives of 7-aminocephalosporanic acid

2nd generation: for oral administration



R¹= -H, R²= -CH₃

cefalexin

Cefaclen[®] cps.

R¹= -OH, R²= -CH₃

cefadroxil

Biodroxil[®] tbl. obd.

R¹= -H, R²=Cl


cefaklor

Ceclor[®] cps.

Cephalosporins


Compounds related to cephalosporin C, i.e. N-acylderivatives of 7-aminocephalosporanic acid

2nd generation: for parenteral use but with ↑ effect to G⁻, ↑ resistance to β-lactamases



cefazolin

Kefzol[®] inj. sic.




cefsulodin

•*Pseudomonas*


Cephalosporins

Compounds related to cephalosporin C, i.e. N-acylderivatives of 7-aminocephalosporanic acid

2nd generation: for both parenteral and p.o. administration, very resistant to β -lactamase




cefamandole



R = H-

cefuroxime

Ceroxim[®] tbl.



R =


cefuroxime axetil

Zinnat[®] tbl. obd.

Cephalosporins

Compounds related to cephalosporin C, i.e. N-acylderivatives of 7-aminocephalosporanic acid


3rd generation: for both parenteral and p.o. administration, very resistant to β -lactamase



cefotaxime

Claforan[®] inj. sic.


R = H- **cefpodoxime**



Cephalosporins


Compounds related to **cephamycin C**, i.e. N-acylderivatives of 7-methoxy-7-aminocephalosporanic acid

„**New class**“ – for both parenteral and p.o administration – resistant to β -lactamase




cefoxitin

Mefoxin[®] inj. sic.



cefminox

Cephalosporin analogues



moxalactam


- dihydrooxazine derivative related to 4th generation of cephalosporins
- developed especially for treatment of meningitis (crosses the blood-brain barrier) and anaerobic infections

Macrolides

- makrocyclic lactones with 10 – 40membered ring with 1 aminomonosaccharide and 1 „neutral“ monosaccharide which can have an additional aminosaccharide attached
- 1st group (with larger ring)- natamycine, nystatine, amphotericine B – see antimycotics
- 2nd group – **erythromycine group** (erythromycine and its analogues, spiramycine, tylosine)

Common structure of narrower group of erythromycine

(14 -15membered laktone ring - erythromycine and analogues)



R¹= -OH, -H

Z = \uparrow C=O, -CH₂N(CH₃)-, \uparrow C=N-O-CH₃, \uparrow C=NOCH₂OCH₂CH₂OCH₃


R²= -H, -F

R³= -H, -CH₃

R⁴= -CH₃ or R² + R⁴= oxirane

Macrolides

Site & mechanism of action



Macrolides

Site and mechanism of action

- **Proteosynthesis inhibition**

- act at 50S ribosome subunit

- inhibit the translocation of growing peptide from acceptor (A) to peptide (P) site

- **bacteriostatic effect**


Spectrum:

- both G⁺ and G⁻

Neisseria, Haemophilus, Brahmanella, Legionella ...


Macrolides

Erythromycine and its analogues



erythromycine

- isolated 1952 from *Streptomyces erythreus*
 - poor biological availability ⇒ lipophilic salts (stearate, ethylsuccinate ...)
 - external form (lotions ...) – treatment of *acne vulgaris*
- Porphyrocin[®] tbl.




azithromycine

- semi-synthetic compound
- Sumamed[®] tbl. o.b.d.


Macrolides

Synthesis of azithromycin from erythromycin




Macrolides

Erythromycin and its analogues



6-O-methylerythromycin
clarithromycin


•also some strains of *Mycobacterium avium*
Klacid® tbl. obd.




roxithromycin
Rulid® tbl.

Macrolides

Erythromycin and its analogues




8-fluoroerythromycin
flurithromycin



dirithromycin


Macrolides

Erythromycin and its analogues



oleandomycin


•isolated 1954 from *Streptomyces antibioticus*



lexithromycin


„More free“ erythromycin analogues: **Ketolides**

- 2 keto-moieties on lactone ring (+ 1 ester carbonyl + 1 carbamate carbonyl)
- good biological availability




Macrolides

Compounds with 16membered lactone ring unsaturated in positions 10 and 12




Macrolides

Compounds with 16membered lactone ring unsaturated in positions 11 and 13



rokitamycin

miokamycin



Aminoglycosides

→ aminosaccharide glycosides produced by strains of *Streptomyces* genus

- Streptomycin group

- Neomycin group

- Kanamycin and gentamycin group

Mechanism of action

- **proteosynthesis inhibition**

- they avoid accurate reading of the genetic code and binding of peptidyl-tRNA to the peptide binding site

- **effect bacteriostatic – bactericidal**


Spectrum

G⁺ < G⁻

Bacillus anthracis, Bordetella pertussis, Brucella, Corynebacterium diphtheriae, E. coli, Enterobacter, Haemophilus, Mycobacterium tuberculosis...

Aminoglycosides

1. Streptomycin group



R = -CHO

streptomycin

- isolated 1944 from *Streptomyces fradiae*
- used to *M. tuberculosis* in combination with other tuberculostatics
- bactericidal

Streptomycin „Grünenthal“[®] inj. sic., Streptowerfft[®] a.u.v


R = -CH₂OH

dihydrostreptomycin

Depomycine[®] a.u.v. inj. (+ benzylpenicillin)

Aminoglycosides

2. Neomycin group



R = -NH₂ **neomycin B**

•mixture of neomycins isolated from *Streptomyces fradiae* in 1949

Framykoin[®] ung., Pamycon[®] plv. (+ bacitracin)

R = -OH **paromomycin**

•not absorbed from GIT


•used for *Entamoeba histolytica*

Humatin[®] cps.


Aminoglycosides

3. Group of kanamycin and gentamicin

Kanamycin subgroup




R = -H **kanamycin**
Kanacol® a.u.v. inj.



tobramycin


Tobi Nebuliser Solution® inh. sol.

•treatment of chronic pulmonary infection caused by *Pseudimonas* in patients with cystic fibrosis



Aminoglycosides




3. Group of kanamycin a gentamycin Subgroup of gentamycin



R¹= H-

H-

CH₃CH₂-



gentamycin

Garasone® gtt. opht.
(+betamethason)
Diagen® a.u.v.

sisomycin

netilmycin

Netromycine® inj.
•serious infections,
sepsis ...